Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Granger

Showing results (691-700 of 1,253) with videos related to

Pageof 126
Sort By:
Circulation|October 7, 2004
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programScott D Solomon, Duolao Wang, Peter Finn, et al.
American Heart Journal|October 8, 2005
Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trialAlejandro Barbagelata, Marcelo F Di Carli, Robert M Califf, et al.
JAMA Cardiology|December 16, 2020
Assessing the Role of Rare Genetic Variation in Patients With Heart FailureGundula Povysil, Olympe Chazara, Keren J Carss, et al.
JAMA Internal Medicine|December 9, 2014
Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data RegistryAmit N Vora, DaJuanicia N Holmes, Ivan Rokos, et al.
Prehospital Emergency Care|March 18, 2016
Therapeutic Hypothermia for Patients with Out-of-Hospital Cardiac Arrest in North CarolinaMeena P Rao, Matthew E Dupre, Sean D Pokorney, et al.
Circulation|October 9, 2014
Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialLars Wallentin, Ziad Hijazi, Ulrika Andersson, et al.
European Journal of Internal Medicine|February 19, 2026
Major adverse cardiovascular and bleeding outcomes in paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient-level data analysis of a large cohort of patients from the COMBINE-AFGeorge Ntaios, Andreas Goette, Michael G Palazzolo, et al.
Circulation|August 20, 2003
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trialChristopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, et al.
Journal of the American Heart Association|December 7, 2021
Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS TrialMarat Fudim, Daniel M Wojdyla, John H Alexander, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trialMichael P Hudson, Paul W Armstrong, William W O'Neil, et al.
Pageof 126

Showing results (691-700 of 1,253) with videos related to

Sort By:
Pageof 126
Circulation|October 7, 2004
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programScott D Solomon, Duolao Wang, Peter Finn, et al.
American Heart Journal|October 8, 2005
Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trialAlejandro Barbagelata, Marcelo F Di Carli, Robert M Califf, et al.
JAMA Cardiology|December 16, 2020
Assessing the Role of Rare Genetic Variation in Patients With Heart FailureGundula Povysil, Olympe Chazara, Keren J Carss, et al.
JAMA Internal Medicine|December 9, 2014
Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data RegistryAmit N Vora, DaJuanicia N Holmes, Ivan Rokos, et al.
Prehospital Emergency Care|March 18, 2016
Therapeutic Hypothermia for Patients with Out-of-Hospital Cardiac Arrest in North CarolinaMeena P Rao, Matthew E Dupre, Sean D Pokorney, et al.
Circulation|October 9, 2014
Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialLars Wallentin, Ziad Hijazi, Ulrika Andersson, et al.
European Journal of Internal Medicine|February 19, 2026
Major adverse cardiovascular and bleeding outcomes in paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient-level data analysis of a large cohort of patients from the COMBINE-AFGeorge Ntaios, Andreas Goette, Michael G Palazzolo, et al.
Circulation|August 20, 2003
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trialChristopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, et al.
Journal of the American Heart Association|December 7, 2021
Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS TrialMarat Fudim, Daniel M Wojdyla, John H Alexander, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trialMichael P Hudson, Paul W Armstrong, William W O'Neil, et al.
Pageof 126